Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells

YANG LI1,2, KE Huang1,2, LING LIU3, YUHUA QU4, YAN HUANG1,2, YANFENG WU1,5 and JING WEI1,6

1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation; 2Department of Pediatric Hematology/Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510120; 3Department of Pediatric, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524000; 4Department of Pediatrics, Guang Zhou Women and Children's Medical Center; 5Biotherapy Center; 6Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China

Received October 15, 2017; Accepted October 4, 2018

DOI: 10.3892/ol.2018.9630

Abstract. Accumulating evidence indicates that the anti-CD20 monoclonal antibody rituximab significantly improves the clinical prognosis of patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. However, a number of patients relapse or fail to respond to rituximab. To further understand the cause of this, polymorphisms of FcγRIIIa were initially detected in healthy volunteers. Subsequently, the rituximab-dependent natural killer (NK) cell-mediated cytotoxicity of different FcγRIIIa genotypes was assessed by a cytotoxicity assay in vitro. Ultimately, the effect of human serum immunoglobulin (Ig) G and complement on rituximab-dependent NK cell-mediated cytotoxicity was evaluated in vitro. It was revealed that FcγRIIIa polymorphisms were associated with the antibody-dependent cell-mediated cytotoxicity (ADCC) of NK cells. In addition, the ADCC of NK cells with FcγRIIIa-158 V/V was increased compared with that of FcγRIIIa-158 V/F. The serum IgG and rituximab Fc segment was able to bind competitively with NK cell FcγRIIa. It was observed that serum IgG inhibited, whereas complement enhanced rituximab-induced NK-cell mediated ADCC. Therefore, various agents administered synchronously with rituximab may modulate the efficacy of this agent and ultimately its toxicity against tumor cells.

Introduction

The therapeutic use of monoclonal antibodies (mAbs), such as rituximab and trastuzumab, has evolved into a promising approach to the treatment of cancer over the last several years (1,2). However, the use of mAbs is effective in only a proportion of the patients; thus, we must investigate the mechanism of action of these immunoreactive mAbs. Rituximab is a chimeric anti-CD20 immunoglobulin G1 (IgG1) mAb that has demonstrated significant therapeutic activity in B-non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL) (3-5). Rituximab induces B-lymphoma cell lysis, which is considered to occur mainly through immune-mediated mechanisms: Antibody-dependent cell-mediated cytotoxicity (ADCC) (6), complement-dependent cytotoxicity (CDC) (7), induction of apoptosis (8) and/or antibody-dependent phagocytosis (ADCP) by macrophages/monocytes (9). Clinical studies have demonstrated that ADCC is one of the most important mechanisms enhancing the therapeutic efficacy of mAbs (10-13).

Natural killer (NK) cells are the most important effector cells for ADCC. Different isotypes of mAbs bind to FcγRIIIa (expressed by NK cells) with a highly variable affinity, which appears to be a determining factor for the efficacy of NK cell-mediated ADCC. Previously, Ravetch et al (14) described a polymorphism in the membrane-proximal domain of FcγRIIIa. A nucleotide substitution at position 559 (G to T) of FcγRIIIa indicates either a valine or a phenylalanine at amino acid position 158 of FcγRIIIa, which results in three genotypes of FcγRIIIa: FcγRIIIa-158 F/F, FcγRIIIa-158 V/V and FcγRIIIa-158 V/F. Polymorphisms (V/V/FF/F) of FcγRIIIa markedly affect the binding affinity of mAbs, particularly the IgG1 isotype, and has been observed in multiple malignancies by its association with the degree of lysis of tumor cell targets in vitro (15-17). Normal serum levels of IgG may effectively compete with IgG1 for binding to low-affinity FcγRIII (CD16) in vivo, resulting in low ADCC of the IgG1 antibody (18). Rimawi MF (19) found that physiological levels of IgG in human serum strongly inhibited the ADCC of trastuzumab, and this inhibition could be fully reversed by adding trastuzumab. The competition of serum IgG with therapeutic...
IgG1 for binding to NK cells may be an explanation as to why high antibody doses are required when treating cancer by ADCC-based mechanisms. Some studies (20,21) also suggested that adding fresh frozen plasma (FFP) to rituximab may provide an effective therapeutic option for patients with advanced CLL who are resistant to chemotherapy. As the specific mechanism underlying the effect of human serum IgG and complement on the anti-tumor efficacy of mAbs has not been fully elucidated, in this study, we used nested polymerase chain reaction (PCR) to detect FcγRIIIa polymorphisms in healthy volunteers, we investigated how the different FcγRIIIa genotypes affect the response of rituximab-dependent NK cell-mediated cytotoxicity by a cytotoxicity assay, and we evaluated the effect of human serum IgG and complement on rituximab-dependent NK cell-mediated cytotoxicity against tumor cells in vitro.

**Subjects and methods**

**Ethics statement.** Blood samples were obtained from 10 healthy volunteers (50% of whom were female), 5 for FcγRIIIa-158 V/V and 5 for FcγRIIIa-158 V/F. Written informed consent was obtained from all the subjects. All the volunteers were aged 25-30 years. The study protocol was approved by the Ethics Committee of Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University.

**Nucleic acid extraction and allele-specific PCR for FcγRIIIa genotyping.** Genomic DNA was purified from peripheral blood leukocytes using the Universal Genomic DNA Extraction kit v.3.0 (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer’s instructions. The FcγRIIIa-158 V/F polymorphism was identified by an allele-specific oligo-hybridization of a nested PCR amplification of genomic DNA (22). A gene-specific 1.2-kb fragment was amplified using the following sense and antisense primers (synthesized by Sangon Biotech, Shanghai, China), 5’-TGG CAAAGGCCAGGAGTATT-3’ and 5’-GCGTGTAAGAAT CAGGAATCTC-3’ in a 25-µl reaction with 3 µl of genomic DNA, 2 pmol of each primer, 0.5 µl of 10 mmol/l dNTP, 2.5 µl of 10X PCR buffer and 1.5 U Taq polymerase. The PCR conditions were as follows: 5 min of initiation denaturation at 95°C, followed by 35 cycles at 95°C for 45 sec, 64°C for 45 sec, and 72°C for 30 sec. One µl of this reaction was transferred to a separate microfuge tube for nested PCR in a total volume of 25 µl, which contained 0.25 pmol of sense and antisense primers, 5’-ATCAGATCGATCCATCTTCT CAGGGGCGAT-3’and 5’-ACGTTGAGCTGACGTG ATGATGTGGATTTGAC-3’, 0.5 µl of 10 mmol/l dNTP, 2.5 µl 10X PCR buffer and 1.5 U Taq polymerase. The PCR conditions for the second amplification consisted of 35 cycles at 95°C for 45 sec, 65°C for 45 sec, and 72°C for 30 sec. The PCR products were visualized on a 3% agarose gel. A total of 8 µl of the final PCR reaction was digested by IalIII restriction enzyme at 37°C overnight, and the products were visualized on 15% PAGE gel by silver staining.

**NK cell preparation.** The blood samples were layered onto Ficoll-Hypaque, and the peripheral blood mononuclear cells (PBMCs) were isolated by gradient centrifugation (23,24).

These cells were washed twice in phosphate-buffered saline (PBS) and re-suspended at a concentration of 5x10⁶/ml for the NK cell ADCC. The cell surface markers CD3, CD56 and FcγRIIIa (CD16a) were analyzed by flow cytometry prior to ADCC. FcγRIIIa-positive PBMCs may be an alternative to FcγRIIIa-positive NK cells as effector cells, which has been widely used in the immunology and clinical fields; thus, mononuclear cells were used as the ADCC effector cells in the present study (25-27).

**Culture of Raji cells.** Raji cells (Human Burkitt’s lymphoma cell line), which highly express the CD20 antigen on their surface, were provided by the Shanghai Institute of Cell Bank. Raji cells were grown and maintained in RPMI 1640 (Gino Biomedical Technology, Hangzhou, China) supplemented with 10% fetal calf serum (FCS; Gino Biomedical Technology) at 37°C, 5% CO₂. The cell surface marker CD20 was analyzed by flow cytometry prior to ADCC.

**Determination of the optimal concentration of rituximab for blocking CD20 on Raji cells in vitro.** Raji cells were harvested and plated in 96-well culture plates at a defined density (1x10⁶/ml) and the regular medium was exchanged to medium containing 10, 20, 30, 40 and 50 µg/ml rituximab (Roche, Shanghai, China). CD20 was tested after 30 min at 37°C by flow cytometry, and the optimal rituximab concentration was determined as that able to completely block CD20 in Raji cells.

**Serum IgG.** Serum was obtained by centrifugation of peripheral blood from healthy volunteers, and coagulation was allowed for 20 min followed by centrifugation of the collection tubes. Immediately after centrifugation, serum was aliquoted in 1.5-ml polypropylene tubes and frozen at -20°C until use. When processing, serum was defrosted and diluted in 1:1 with RPMI 1640, producing a medium with 50% human serum (containing complement).

**Serum IgG and FcγRIIIa binding assays in the absence of mAb.** The binding of serum IgG to FcγRIIIa on NK cells was studied by flow cytometry. Briefly, 0.1 ml of 5x10⁶/ml PBMCs were incubated in the absence or presence of 4.8 mg/ml human serum IgG for 30 mins at 37°C in a 5% CO₂ incubator, washed twice with PBS, followed by flow cytometric analysis of cell-bound FcγRIIIa.

**Cytotoxicity assay.** The cytotoxicity assay was divided into two groups (FcγRIIIa V/V and FcγRIIIa V/F) according to the FcγRIIIa genotypes of NK cells, and each group was further subdivided into four groups: Negative control, ADCC, ADCC+CDC and serum IgG groups. Raji cells were labeled with DIO (Beyotime Biotechnology, Jiangsu, China) at 37°C for 30 min and washed three times with PBS to remove unreacted and unbound DIO. A total of 3 µl of 0.1 µg/µl rituximab...
was added to the ADCC, ADCC+CDC and serum IgG groups, and serum was added to the serum IgG group at the same time. Each group was incubated for 4 h at 37°C in a 5% CO₂ incubator, and then the labeled target cells were re-suspended in RPMI 1640 containing 10% FCS (only the ADCC+CDC group was re-suspended in RPMI 1640 containing 50% human serum) and mixed with PBMCs at an effector/target ratio (E/T) of 5:1. All the cells were incubated at 37°C for 4 h and washed twice with PBS, followed by the addition of 5 µl propidium iodide (PI) (Beyotime Biotechnology). Finally, cells were analyzed by flow cytometry after a 30-min incubation in the dark. The negative control did not contain PBMCs. The percentage of killed cells was calculated as follows: (% of living cells in negative control-% of living cells in sample)/% of living cells in negative control.

Statistical analysis. The results are expressed as the mean ± standard error of the mean, and the data were analyzed by SPSS 16.0 statistical software. An independent samples t-test was used to evaluate the difference between FcγRIII-positive PBMC and FcγRIII-positive NK cells in PBMCs. The expression levels of FcγRIIIa in NK cells before and after adding serum in the absence of mAb in vitro were also analyzed using an independent samples t-test. The comparison of cytotoxic index between the groups with multivariate analysis of variance, after the equal check of variance, and the two-two comparisons among the means were performed using the Student-Newman-Keuls method. P<0.05 was considered to indicate a statistically significant difference.

Results

Human PBMCs may be an alternative to NK cells as the effector cells. In this study, the results demonstrated that 20.91±2.12% of PBMCs were CD3+CD56+ NK cells (Fig. 1A), and the expression level of FcγRIII on NK cells was 91.29±6.53% (Fig. 1B). A total of 19.24±0.78% of PBMCs expressed FcγRIII (Fig. 1C), and NK cells expressing FcγRIII accounted for 19.02±0.57% of PBMCs (Table I and Fig. 2); thus, NK cells were the main FcγRIII-positive cells in PBMCs. Therefore, FcγRIII-positive PBMCs may be an alternative to FcγRIII-positive NK cells as effector cells in our experiment, which was also confirmed by other studies (25-27).

Optimal concentration of rituximab for blocking CD20 on Raji cells. In order to establish the peak dose of rituximab for saturating CD20 on Raji cells, rituximab was added to the medium with Raji cells (1x10⁶/ml) at sequential concentrations of 10, 20, 30, 40 and 50 µg/ml in different groups. After incubating for 30 min at 37°C, the levels of CD20 on Raji cells decreased in a dose-dependent manner to 6.16, 3.60, 0.38, 0.29 and 0.27%, respectively, CD20 downregulation was first noted at a rituximab concentration of 10 µg/ml, reaching a plateau at concentration of 30 µg/ml. There was no significant difference among the last three groups (P>0.05); thus, 30 µg/ml was selected as the optimal concentration of rituximab for blocking CD20 in subsequent experiments.

Normal human serum does not affect the expression of FcγRIIIa in NK cells. To clarify whether normal human serum affects the expression of FcγRIIIa in NK cells in vitro, we examined the expression of FcγRIIIa in NK cells before and after the addition of serum in the absence of mAb in vitro, and it was found to be 91.16% (Fig. 3), compared with that before adding normal human serum; the difference was not statistically significant.

Complement enhances NK cell cytotoxicity induced by rituximab-coated Raji cells. We performed an in vitro ADCC assay with the Human Burkitt's lymphoma cell line Raji as target cells, human PBMC as effector cells and rituximab as human IgG1 mAb. In the ADCC group, with the absence of human serum, NK cells with different FcγRIIIa genotypes exerted various cytotoxic effects on Raji cells. The cytotoxic indices of NK cells with the FcγRIIIa-158 V/V genotype were 69.05±2.38 and 39.63±3.86%, respectively (Table II, Figs. 4 and 5), with the cytotoxic index of NK cells with the FcγRIIIa-158 V/F genotype being significantly higher compared with that of the FcγRIIIa-158 V/F genotype (n=5, P<0.05 in all cases).

Irrespective of the group, the cytotoxic index in NK cells with the FcγRIIIa-158 V/V genotype was significantly higher compared with that of the FcγRIIIa-158 V/F genotype (n=5, P<0.05 in all cases). Irrespective of the FcγRIIIa-158 genotype,
the cytotoxic index in the ADCC+CDC group was significantly higher compared with that in the ADCC group, and the cytotoxic index in the ADCC group was higher compared with that in the serum IgG group (n=5, P<0.05 in all cases).

In group ADCC+CDC, replacement of 50% of the assay buffer with human serum containing complement strongly enhanced ADCC by rituximab, and the cytotoxic index in the ADCC+CDC group was significantly higher compared with that in the ADCC group (P<0.05), irrespective of the FcγRIIIa-158 genotype (Table II, Figs. 4 and 5).

Normal human serum inhibits NK cell cytotoxicity induced by rituximab-coated Raji cells. In order to identify the effect of human serum on ADCC, 40% of the assay buffer was replaced with human serum (containing human IgG; complement was inactive) in the serum IgG group. The result revealed that the cytotoxic index in the serum IgG group was lower compared with that in the ADCC group (P<0.05). The inhibitory effect of human serum on ADCC by rituximab was obvious, irrespective of the FcγRIIIa-158 genotype (Table II, Figs. 4 and 5).

Discussion

FcγRs are the key link between humoral and cellular immune responses. They are important in immune regulation and mediate ADCC, endocytosis, phagocytosis, release of inflammatory cytokines and antigen presentation (29). There are three classes of FcγRs: FcγRI (CD64) FcγRII (CD32) and FcγRIII (CD16), with FcγRIII further subdivided into FcγRIIa and FcγRIIb (30). FcγRIIa is a transmembrane glycoprotein, which is expressed on monocytes, macrophages, NK cells and some T cells, while FcγRIIb is only expressed on neutrophils and IFN-γ-induced eosinophils (31). In the present study, we found that the FcγRII on NK cells was all FcγRIIIa. The expression of FcγRIII on PBMNCs was 19.24±0.78%, and that on NK cells was 19.02±0.57%; therefore, the FcγRIII-positive PBMNCs were essentially FcγRIII-positive NK cells and are referred to as effector cells in our experiment (29-31).

Previous studies (10,11,32-35) demonstrated that polymorphisms of FcγRIIIa on NK cells result in variable affinity for mAbs, subsequently affecting the ADCC. The therapeutic efficacy of mAbs in patients with the FcγRIIIa-158 V/F genotype is superior to that in patients with the FcγRIIIa-158 V/F and FcγRIIIa-158 F/F genotypes. Hatjiharissi et al (36), found that patients with NHL expressing at least one valine at FcγRIIIa-158 may, in part, exhibit a better therapeutic response to mAb treatment. In the present study, we determined the effect of FcγRIIIa polymorphism on ADCC activity of rituximab-dependent NK cells, and our experimental results demonstrated that the ADCC activity of NK cells with FcγRIIIa-158 V/F was higher compared with that of FcγRIIIa-158 V/F, in accordance with the abovementioned reports.

A nucleotide substitution at position 559 of FcγRIIIa predicts either a valine or a phenylalanine at amino acid position 158 of FcγRIIIa, and results in three genotypes of FcγRIIIa, namely FcγRIIIa-158 F/F, FcγRIIIa-158 V/F and FcγRIIIa-158 F/V (14). Dal’Ozzo et al (16) detected circulating CD16+ mononuclear cells in these three FcγRIIIa genotype subsets, demonstrated that the expression of CD16 on NK cells did not change significantly, and FcγRIIIa-158 V exhibited a higher affinity to rituximab compared with FcγRIIIa-158 F, as the former can bind more strongly to the mAb Fc segments, resulting in enhancement of rituximab-mediated ADCC. Hatjiharissi et al (36) also demonstrated that FcγRIIIa-158 V/F may increase rituximab binding, which was confirmed by Dal’Ozzo et al (16). Therefore, according to the results of
previous studies (16,36) and our findings, NK cells with the FcγRIIIa-158 V allele have a higher affinity for rituximab, suggesting a more effective rituximab-mediated ADCC compared with those having the FcγRIIIa-158 F allele; these findings may help improve the elimination of tumor cells to achieve a better therapeutic effect.

The complement system is composed of >30 soluble plasma proteins and membrane proteins that can trigger three distinct protease cascades known as the classical, mannose-binding lectin (MBL), and alternative pathways (37). When the complement system is activated, the membrane attack complex (MAC) is inserted into the cell membrane and directly induces the lysis of targeted cells through subsequent influx of ions and water, leading to lethal colloid-osmotic edema (CDC). CDC and ADCC are both suggested as being important for rituximab-mediated tumor cell eradication; however, the determinant mechanisms remain unknown. Van Meerten et al (38), established an experimental system in which the CD20 molecule is the only variable factor, and the results suggested that the CDC activity of rituximab depends on the level of CD20 expression. Other studies (39,40) also reported a linear correlation between CD20 and CDC, demonstrating that rituximab-mediated CDC depends on the expression level of CD20.

In the present study, we investigated the changes in rituximab-dependent NK cell-mediated cytotoxicity in Raji cells after adding serum complement in vitro, in order to elucidate the role of serum complement in mAb-dependent NK cell-mediated cytotoxicity against tumor cells. Our results demonstrated that rituximab-mediated cytotoxicity in the presence of complement was significantly enhanced. Other studies (38,40) demonstrated that, as the C1q and FcγRIIIa binding sites were in close proximity, following rituximab binding to CD20, the C1q of complement binds to the CH2 domain of IgG1, thereby triggering the classic complement pathway that finally activates CDC, which supports the results of our study. Anaphylatoxin C5a, the by-product of CDC, interacting with the C5a receptor, can upregulate the expression of FcγRIIIa on effector cells, downregulate the expression of inhibitory receptors FcγRIIb, activate effector cells and enhance the mAb-mediated ADCC antitumor effect (18,41-44). In the presence of mAb, the activity of CDC depends on the CD20 expression level. When CDC is activated, ADCC is synchronously promoted. CDC and ADCC interact in a complementary manner and enhance mAb-dependent NK cell-mediated cytotoxicity in vitro. Plasma contains complement, which can effectively activate the classic complement pathway to trigger CDC, promote ADCC and mediate cytotoxicity targeted against tumor cells. Our findings indicate that CDC plays a key role in tumor cell elimination, and complement blocks rituximab-induced NK-cell-mediated ADCC.

As is well-known, human IgG1 mAb, which is commonly used in cancer treatment, requires a higher blood concentration; however, the reason as to why the strong ADCC of anticancer mab in vitro is contrasted by its weakness in vivo has not yet been fully elucidated. Some researchers (18,45) observed that physiological levels of IgG in human serum strongly inhibited the ADCC of the IgG1 antibody, which may be one of the reasons explaining why ADCC of mAb is sometimes suppressed in vivo. In our study, we detected the changes in rituximab-dependent NK cell-mediated cytotoxicity against Raji cells by adding serum IgG in vitro, aiming to investigate the effect of serum IgG on mAb-dependent NK cell-mediated cytotoxicity. Our results demonstrated that rituximab-mediated cytotoxicity in the group with the addition of serum was significantly reduced compared with that in the group without serum addition, which is consistent with the results of other studies (18,45-48). Preithner et al (18), demonstrated that removal of serum IgG abolished the inhibitory effect on ADCC, while this could be fully reversed by adding exogenous serum IgG, indicating that physiological levels of human serum IgG could inhibit the ADCC of mAb in vitro. Nechansky et al (28) reported that mAb diluted in 40% of normal human serum (NHS), containing high amounts of endogenous IgG (~4.8 mg/ml), resulted in a significantly lower ADCC activity compared with that diluted in 10% FCS, which contains less IgG (~10 µg/ml), indicating that the high IgG content in NHS can significantly decrease the ADCC activity mediated by mAbs. Further research demonstrated that physiological level of human serum IgG can also impair the ADCC of the therapeutic mAb in vivo by competitively binding to FcγRIIIa on the effector cells (18,46-48), thus resulting in inhibition of mAb-mediated ADCC. Our results also indicated that serum IgG competes with rituximab Fc...
segments for binding to the FcγRIIIa, thus interfering with the antitumor effect of rituximab.

Furthermore, we examined the ratio of FcγRIIIa expression on NK cells before and after adding serum in the absence of mAb, which was 95.91 and 91.16%, respectively; interestingly, the difference was not statistically significant. Although we demonstrated that serum did not significantly affect the blockade of FcγRIIIa on NK cells, it did ultimately inhibit ADCC of rituximab. This may be explained by the following hypotheses: ADCC is usually investigated in the absence of human serum through the quantification of target cell lysis by the addition of effector cells to the mixture of mAbs and target cells. Previous studies have demonstrated that the primary activating FcγR on NK cells is the low-affinity type III receptor (CD16) (48, 49). NK cell-bound endogenous IgG may be rapidly displaced by the mAb IgG1 due to an avidity effect when it forms a polyvalent CD16-binding matrix on the surface of its target cell (18); therefore, if the serum IgG does not combine with epitopes on the target cells in advance, the affinity of the free serum IgG to NK cells may be low and the serum appears to exert no significant effect on the blockade of FcγRIIIa on NK cells. However, in our experiment, the serum IgG concentration (0.5-0.9 mg/ml (18)) was ~17-30 times that of rituximab (30 µg/ml) in the serum IgG group; this high difference in concentration and resulting competitive effect may at least in part account for the serum IgG combining...
with FcγRIIIa more effectively and inhibiting the ADCC of rituximab. We observed that replacement of 50% of the assay buffer with human serum containing complement strongly enhanced ADCC by rituximab. This enhanced ADCC was not in line with previous results (50) and the specific underlying mechanism is not clear. The observed enhanced killing of tumor cells may also be the consequence of simultaneous induction of ADCC and CDC, and CDC may participate in blocking this reaction, while allowing opsonization with complement components. Although these are possible explanations, further investigation is required to fully elucidate the specific underlying mechanisms.

The rituximab-mediated ADCC may be inhibited by the presence of serum IgG; thus, serum IgG may interfere with the efficacy of rituximab. Due to the presence of serum, we hypothesized that the ADCC efficacy of IgGl antibodies in vivo would be low, despite it being high in vitro, so that antitumour efficacy in the clinical setting usually requires large doses of mAb to maintain a high serum level. Our findings demonstrated that serum IgG plays a negative role in tumor cell elimination.

In summary, the present study suggests that FcγRIIIa polymorphism in NK cells may modulate the ADCC activity of rituximab, and the ADCC activity of NK cells with FcγRIIIa-158 V/V is higher compared with that with FcγRIIIa-158 V/F. Additionally, serum IgG inhibits rituximab-mediated ADCC, and complement can effectively enhance ADCC, both of which are involved in mediating the cytotoxicity of rituximab in opposite ways. Although either complement or serum IgG can also affect the cytotoxic ability against non-CD20-expressing tumor cells, a large volume of evidence shows that loss of CD20 expression results in inhibition of anti-CD20 mAb (rituximab) binding, and a CD20-negative phenotypic change after treatment with rituximab can be found, with relapse or progression in a number of CD20-positive B-cell lymphoma patients, indicating a correlation between the CD20 expression and rituximab sensitivity (51-53). Therefore, in this experiment we did not select CD20-negative cells as the target cells. Due to time and funding limitations, in this experiment we set the polymorphism of FcγRIIIa on NK cells as the only variable, and set the optimal dosage (according to the conclusion of the preliminary experiment or reference) of complement or serum IgG as a constant, so there are no data on the association between the concentration of complement or serum IgG and cytotoxicity. To better elucidate this issue, selecting more tumor cell lines with or without expression of CD20 may help provide a better explanation of the underlying mechanism, as further data accumulation is required.

Acknowledgements

Not applicable.

Funding

The present study was supported by grants from the Guang Dong Natural Science Foundation (grant no. 2014A030313024); the Guangdong Science and Technology Department (grant no. 2015B050501004); the Foundation of the Ministry of Education of China for Returned Scholars (grant no. 2009036) and the Guang Dong Science Research Program (grant no. 2010B080701074).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request. Authors' contributions

YL was responsible for the experiment and wrote the manuscript. KH performed the design of experiment and collection of the samples. LL and YQ analyzed the experiment data. YW, YH and JW were accountable for performing data interpretation and revising the manuscript.

Ethics approval and consent to participate

The study protocol was approved by the Ethics Committee of Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University and written informed consent was obtained from all participants.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Keating GM: Rituximab: A review of its use in chronic lymphocytic leukemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70: 1445-1476, 2010.
2. Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, Andrade S and Batel-Marques F: The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer-a systematic review. Breast Cancer Res 17: 140, 2015.
3. Martin P, Furman RR, Coleman M and Leonard JP: Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Clin Cancer Res 13: 5636s-5642s, 2007.
4. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377: 42-51, 2011.
5. Tam CC, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khoury I, Kantarjian H, et al: Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood 124: 3059-3064, 2014.
6. Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ, et al: Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108: 2648-2654, 2006.
7. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grievo V, Scanziani E, Botto M, Introna M and Golay J: Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171: 1581-1587, 2003.
8. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D and Reed JC: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 99: 1038-1043, 2002.
9. Weiner GJ: Rituximab: Mechanism of action. Semin Hematol 47: 115-123, 2010.
10. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Remberger M, Therrien T: Humanization of anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99: 754-758, 2002.
11. Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, Yun S, Joo J and Kim HJ: Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: Influence of FCGRA3 polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72: 989-995, 2015.
12. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliaeube E, Castiglioni F, Villani L, Magalotti C, Gibelli N, et al: Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650-5655, 2004.
13. Zhang W, Gordon M, Schultheis AM, Ye J and Hui RT: Effect on the cytotoxicity of NK cells with complement in autoimmunity. Immunol Lett 100: 56 -67, 2006.
14. Ravelov JH and Perussia B: Alternative membrane forms of Fc gamma RIICD16 on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med 170: 481-497, 1989.
15. Vaknin-Dembinsky A, Charbit H, Brill L, Abramsky O, Gur-Wahnon D, Ben-Dov I and Lavon I: Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO). J Neuroinflammation 13: 179, 2016.
16. Davidovitz Z, Chandy S, Paini M, Cartron G, Colombat P, Bardos P, Watier H and Thibault G: Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGRA3 polymorphism on the concentration-effect relationship. Cancer Res 64: 4664-4669, 2004.
17. López-Albaitero A, Lee SC, Morgan S, Granjis D, Gooding WE, Ferrone S and Ferris RL: Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58: 1853-1864, 2009.
18. Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, van Meerten T, van Rijn RS, Hol S, Hagenbeek A and Ebeling SB: Complement -mediated cytotoxicity. Clin Cancer Res 12: 4027-4035, 2006.
19. Abraham K, Lugassy G, Kotsianidis I, Rachmilewitz EA and Deeg P and Trzonkowski P: Changed phagocytic activity and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58: 1853-1864, 2009.
20. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, et al: Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc(gamma)RIIIa158 V/V and V/F polymorphism. Blood 110: 2540-2546, 2007.
21. Tateishi K and Matsuhashi S: Activation of the alternative complement pathway by mannos-binding lectin via a C2-bypass pathway. Microbiol Immunol 55: 817-821, 2011.
22. van Meerten T, van Rijn RS, Hol S, Hagenbeek A and Ebeling SB: Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 12: 4027-4035, 2006.
23. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Campo E, Colomer D and Montserrat E: Complement -mediated cytotoxicity. Clin Cancer Res 12: 4027-4035, 2006.
24. Dubaniewicz A, Typiak M, Wybiersalla M, Szadurska M, Nowakowski S, Stainiewicz-Panasiak A, Rogoza K, Sternal A, Deep P and Trzonkowski P: Changed phagocytic activity and pattern of Fc and complement receptors on blood monocytes in sarcoidosis. Hum Immunol 73: 788-794, 2012.
25. Hans VM and Mehta DS: Genetic polymorphism of Fc-receptors IIa, IIIa and IIIb in South Indian patients with generalized aggressive periodontitis. J Oral Sci 53: 467-474, 2011.
26. Preithner S, Elm S, Lippold S, nya M, Chang HM, Borucka E, Lurje G, Martinelli G, Stiehm ER: Effects of anticoagulant, serum, and temperature on the natural killer activity of human peripheral blood mononuclear cells stored overnight. Clin Diag Lab Immunol 3: 260-264, 1996.
27. Duesberg H, Lehtonen H: Therapeutic intervention of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99: 754-758, 2002.
28. Dechant M, Beyer T, Schneider-Merck T, Weissen W, Peipp M, van de Winkel JG and Valierius T: Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 179: 2936-2943, 2007.
29. Boisson B, Laplantine E, Prando C, Giliani S, Israelsson E, Xu Z, Abhyankar A, Israel L, Trevejo-Nunez G, Bogunovic D, et al: Immunodeficiency, autoinflammation and amylolysinosis in humans with inactivating mutations in MASP1 and LUBAC deficiency. Nat Immunol 13: 1178-1186, 2012.
30. Nechansky A, Schuster M, Just W, Siegl P, Wiederkuem S, Gorr G and Kirkeis R: Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glycol-engineering of therapeutic antibodies. Mol Immunol 44: 1-13, 2007.
31. Zhuang Y, Xu W, Shen Y and Li J: Fc receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 10: 347-352, 2010.
32. Dubaniewicz A, Typiak M, Wybiersalla M, Szadurska M, Nowakowski S, Stainiewicz-Panasiak A, Rogoza K, Sternal A, Deep P and Trzonkowski P: Changed phagocytic activity and pattern of Fc and complement receptors on blood monocytes in sarcoidosis. Hum Immunol 73: 788-794, 2012.
43. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, et al: Generation of C5a in the absence of C3: A new complement activation pathway. Nat Med 12: 682-687, 2006.

44. Kumar V, Ali SR, Konrad S, Zvirner J, Verbeek J, Schmidt RE and Gessner JE: Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 116: 512-520, 2006.

45. Carlsten M, Levy E, Karambelkar A, Li L, Reger R, Berg M, Peshwa MV and Childs RW: Efficient mRNA-based genetic engineering of human NK cells with high-affinity CD16 and CCR7 augments rituximab-induced ADCC against lymphoma and targets NK cell migration toward the lymph Node-associated chemokine CCL19. Front Immunol 7: 105, 2016.

46. Deo YM, Graziano RF, Repp R and van de Winkel JG: Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today 18: 127-135, 1997.

47. Dettke M and Loibner H: Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro. Br J Cancer 82: 441-445, 2000.

48. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C and Sun PD: The structure of a human type III Fc receptor in complex with Fc. J Biol Chem 276: 16469-16477, 2001.

49. Sulica A, Morel P, Metes D and Herberman RB: Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int Rev Immunol 20: 371-414, 2001.

50. Wang SY, Racila E, Taylor RP and Weiner GJ: NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 111: 1456-1463, 2008.

51. Nakamaki T, Fukuchi K, Nakashima H, Arizumi H, Maeda T, Saito B, Yanagisawa K, Tomoyasu S, Homma M, Shiozawa E, et al: CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma. Eur J Haematol 89: 280-285, 2012.

52. Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K and Tsuda H: Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. Am J Surg Pathol 37: 563-570, 2013.

53. Duman BB, Sahin B, Ergin M and Guvenc B: Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): A case report and review of the literature. Med Oncol 29: 1223-1226, 2012.